Tag Archives: Aldeyra Therapeutics

Aldeyra Therapeutics (ALDX) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and set a price target of $30. The company’s shares closed yesterday at $10.09. Piros said: “Aldeyra develops a platform of aldehyde trap

Cantor Fitzgerald Believes Aldeyra Therapeutics (NASDAQ: ALDX) Won’t Stop Here

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX), with a price target of $30. The company’s shares closed yesterday at $9.90, close to its 52-week high of $10.64. Piros

Aldeyra Therapeutics (ALDX) Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) today and set a price target of $23. The company’s shares opened today at $7.80. Piros commented: “We reiterate our OW rating. Aldeyra develops a platform

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (NASDAQ: ALDX) and Regulus (NASDAQ: RGLS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aldeyra Therapeutics (NASDAQ:ALDX) and Regulus (NASDAQ:RGLS). Aldeyra Therapeutics (ALDX) In a report released today, John Newman from Canaccord Genuity maintained a Buy rating

Cantor Fitzgerald Reaffirms Their Buy Rating on Aldeyra Therapeutics

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) today and set a price target of $23. The company’s shares opened today at $8.35. Piros wrote: “: We are reiterating our Overweight rating and 12-month

Aldeyra Therapeutics Gets a Hold Rating from Cowen & Co.

In a report issued on April 6, Ritu Baral from Cowen & Co. maintained a Hold rating on Aldeyra Therapeutics (NASDAQ: ALDX). The company’s shares closed on Friday at $7. According to TipRanks.com, Baral is a top 100 analyst with